Open Access. Powered by Scholars. Published by Universities.®
Immunoprophylaxis and Therapy Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Immunoprophylaxis and Therapy
Combinatorial Administration Of Synthetic Tlr4 Agonist Ini-2002 And Novel Mincle Agonist Um-1098 Delivered Via A-Snps Results In Synergistic Il-1Β Production In Human Primary Cells And Enhances Th1 And Th17 Responses In Vivo, Grace D. Jones, Asia Marie Stephanie Riel, Alexander Riffey, Cassandra Buhl
Combinatorial Administration Of Synthetic Tlr4 Agonist Ini-2002 And Novel Mincle Agonist Um-1098 Delivered Via A-Snps Results In Synergistic Il-1Β Production In Human Primary Cells And Enhances Th1 And Th17 Responses In Vivo, Grace D. Jones, Asia Marie Stephanie Riel, Alexander Riffey, Cassandra Buhl
Graduate Student Theses, Dissertations, & Professional Papers
Tuberculosis (TB) kills more people each year than any infectious disease worldwide with recent exception of SARS-CoV-2. Though the Bacille Calmette Guerin (BCG) vaccine confers protection against severe extrapulmonary forms of TB, there is no licensed vaccine for the prevention of pulmonary tuberculosis. The strongest correlate of protection against pulmonary tuberculosis is Th1/Th17 biased cell mediated immunity. Several candidates for TB vaccine adjuvants have shown Th1/Th17 polarizing capacity in clinical trials including Mincle agonist trehalose dibehenate (TDB) and TLR4 agonist monophosphoryl lipid A (MPL). Furthermore, combinatorial administration of MPL and TDB formulated in dimethyldioctadecylammonium (DDA) liposomes has been previously reported …